Nanomerics today announced end of dosing with all volunteers completing the full schedule and without moderate or severe adverse events reported:
Nanomerics reported that it had completed 28 consecutive days of administration in its OC134 Phase I trial – the SUNLIGHT trial. Dosing twice daily (12 h apart) of the healthy study participants with MET eye drops and OC134 eye drops commenced in December 2024 and was completed in January 2025. All volunteers (n=10) completed the dosing schedule, with no drop outs and volunteers will report for follow up assessments in February 2025.
There were no adverse events of moderate or severe severity reported during the clinical phase of the trial and there were no clinically significant individual changes from baseline or notable trends in safety assessments including safety bloods, vital signs, eye examination, 12 lead ECGs and urine analysis.
Single topical administration of MET and OC134 eye drops on 56 consecutive occasions were well tolerated by healthy volunteers under the condition of trial. Approval was granted recently for the OC134 and MET tolerability study by the UK Medicinal and Healthcare Products Regulatory Agency (MHRA) and the study was conducted by Quotient Sciences at its Nottingham, UK Phase I study site according to Good Clinical Practice guidelines.
OC134 is an eye drop medicine candidate indicated for the topical treatment of moderate to severe allergic conjunctivitis, a condition for which a suitable non-steroidal topical ocular treatment, does not currently exist.
OC134 is powered by Nanomerics’ Molecular Envelope Technology (MET), a non-irritant ocular penetration enhancer. Nanomerics’ MET is a platform ocular penetration enhancer, that has been shown in preclinical studies to increase the penetration of active pharmaceutical ingredients (APIs) into the front of the eye; increasing ocular deposition up to 18-fold, when compared to conventional formulations. In preclinical studies, Nanomerics’ MET also demonstrated the delivery of APIs to the retina from eye drops. Nanomerics has a pipeline of ocular assets that may now be tested in clinical studies and ultimately launched for the benefit of patients. Nanomerics’ MET is now a clinical stage ocular excipient.
Professor Andreas G. Schätzlein, Nanomerics’ Chief Executive Officer said,
“We are pleased that Nanomerics has completed the dosing phase of its first clinical study – the SUNLIGHT trial - with Nanomerics’ Molecular Envelope Technology (MET) powered eye drops. This is an important step which will now enable us to move forward our ocular pipeline for later stage clinical testing. We are indebted to our clinical trials partner – Quotient Sciences – for working with us on this Good Clinical Practice trial.”
Dr Nand Singh, Medical Director at Quotient Sciences commented,
“We are pleased that the First-In-Human trial has completed the clinical phase of the study at our Nottingham, UK clinic for Nanomerics’ OC134 Phase 1 SUNLIGHT trial. This trial marks a significant milestone in the development of a new therapeutic approach aimed at developing advanced treatments for moderate to severe allergic conjunctivitis.”
About Nanomerics
Nanomerics Ltd is a speciality pharmaceutical company with state-of-the-art laboratories based in London, UK. Nanomerics was founded to commercialise its biocompatible polymer technologies for drug delivery and other applications. Nanomerics’ proprietary technology is based on world leading know-how and scientific leadership in polymer nanotechnology. Nanomerics creates uniquely differentiated, patented pharmaceutical assets, underpinned by high quality science. For example, the company’s Molecular Envelope Technology (MET) is a unique patented biocompatible polymer that delivers a step change in target tissue bioavailability. The founding scientists, Professor Dame Ijeoma F. Uchegbu and Professor Andreas G. Schätzlein developed the technology at the Universities of Strathclyde and Glasgow and, latterly at the UCL School of Pharmacy. Pharmaceutical product candidates in development include the eye drops: OC134 for the treatment of moderate to severe allergic conjunctivitis, OC137 for the treatment of retinal diseases and OC135 for the treatment of glaucoma. For more information, please visit www.nanomerics.com
For press enquiries contact:
Pedro Margarido
Head of Operations, Nanomerics Ltd.
About Quotient Sciences
Quotient Sciences is a drug development and manufacturing accelerator providing integrated programmes and tailored services across the entire development pathway. Cutting through silos across a range of drug development capabilities, Quotient saves precious time and money in getting drugs to patients. Everything Quotient does for its customers is driven by an unswerving belief that ideas need to become solutions, and molecules need to become cures, fast, because humanity needs novel therapeutic solutions, fast. Quotient Sciences has been recognized as a multi-year winner of the CRO Leadership Awards in 2021, 2022, and 2024 and of the CDMO Leadership Awards in 2023. For more information, visit quotientsciences.com.
For press enquiries, contact:
Erica Fearnley
Executive Director, Strategic Marketing at Quotient Sciences
Rachael Heath
Senior PR Manager at RaMarketing & PR
Comments